Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 659

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 4
Chunk 659
---
 2023; no
                                    shares issued or outstanding
                                     
     -  
     - 
  
    Additional paid in capital 
     64,263,919  
     57,409,643 
  
    Accumulated deficit 
     (60,439,183) 
     (45,417,156)

    Total stockholders’ equity 
     3,944,875  
     12,076,498 

    Total liabilities and stockholders’ equity 
    $7,338,756  
    $14,923,878 

See
accompanying notes to the consolidated financial statements and report of independent registered public accounting firm

F-3

INDAPTUS
THERAPEUTICS, INC.

Consolidated
Statements of Operations and Comprehensive Loss

    2024  
    2023 

    For the year ended December 31, 

    2024  
    2023 
  
    Operating expenses: 

    Research and development 
    $7,251,097  
    $7,621,707 
  
    General and administrative 
     8,114,654  
     8,756,767 

    Total operating expenses 
     15,365,751  
     16,378,474 

    Loss from operations 
     (15,365,751)  
     (16,378,474)

    Other income, net 
     343,724  
     955,003 

    Net loss 
    $(15,022,027) 
    $(15,423,471)

    Net loss available to common stockholders per share of common stock, basic and diluted 
    $(1.61) 
    $(1.83)

    Weighted average number of shares used in calculating net loss per share, basic and diluted 
     9,355,710  
     8,401,047 

    Net loss 
    $(15,022,027) 
    $(15,423,471)
  
    Other comprehensive income: 

    Reclassification adjustment for interest earned on marketable securities included in net loss 
     -  
     (430,993)
  
    Change in unrealized gain on marketable securities 
     -  
     334,559 
  
    Comprehensive loss 
    $(15,022,027) 
    $(